Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 11:09 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 399 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Testosterone Clear all

Conditions: Insulin Resistance, Type 2 Diabetes Mellitus, Obesity, Androgen Deficiency, Metabolic Disease
Interventions: Acyline, Testosterone 1.62% gel, Letrozole, Placebo gel (for Testosterone 1.62% gel), Placebo pill (for Letrozole); Drug
Lead sponsor: University of Washington; Other
Eligibility: 25 Years to 55 Years · Male only
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Peyronie's Disease
Interventions: Vitamin D2, Vitamin E, Testosterone Pellets; Drug
Lead sponsor: Men's Health Boston; Other
Eligibility: 18 Years to 70 Years · Male only
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Chestnut Hill, Massachusetts

Conditions: Klinefelter Syndrome
Interventions: Testosterone Cypionate 200 Milligram/Milliliter Injectable Solution, Placebo injectable saline; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 31 Days to 90 Days · Male only
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Supplement
Interventions: T+ Supplement, Placebo; Other
Lead sponsor: Florida State University; Other
Eligibility: 18 Years to 35 Years · Male only
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Tallahassee, Florida

Conditions: Precocious Puberty
Interventions: Spironolactone, Testolactone, Deslorelin; Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: Male only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1985 – 2004
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Male Hypogonadism, Primary Hypogonadism, Secondary Hypogonadism
Interventions: Testosterone undecanoate; Drug
Lead sponsor: Clarus Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years · Male only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Recurrent Prostate Cancer
Interventions: Testosterone cypionate, Goserelin, Leuprolide; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Male only
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: PCOS
Interventions: Dexamethasone, recombinant human chorionic gonadotropin (r-hCG); Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 12 Years to 18 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Healthy Participants
Interventions: Testosterone, Deodorant Spray, Deodorant and Antiperspirant Combination Spray, Deodorant and Antiperspirant Combination Stick; Drug · Other
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 50 Years and older · Male only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 2
States / cities: Daytona Beach, Florida • Evansville, Indiana

Conditions: Multiple Sclerosis
Interventions: AndroGel 1 % Topical Gel, Placebos; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 60 Years · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 2
States / cities: Los Angeles, California • St Louis, Missouri

Conditions: Hypogonadism, Contraception
Interventions: Testosterone gel, Acyline, Placebo acyline, Placebo Testosterone gel; Drug
Lead sponsor: University of Washington; Other
Eligibility: 35 Years to 55 Years · Male only
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Aging, Obesity, Insulin Resistance, Hypogonadism
Interventions: Topical testosterone gel 10 g/day; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 60 Years to 90 Years · Male only
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2014
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Recurrent Urinary Tract Infection, Vaginal Atrophy, Postmenopausal Disorder
Interventions: Vaginal Cream with Applicator; Drug
Lead sponsor: Jefferson Drapkin; Other
Eligibility: 60 Years to 90 Years · Female only
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Hip Fracture, Testosterone Deficiency, Muscle Weakness
Interventions: Testosterone gel; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 65 Years and older · Female only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Mobility Limitation
Interventions: Testosterone enanthate; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 65 Years and older · Male only
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hypogonadism
Interventions: Fispemifene once daily for 4 weeks; Drug
Lead sponsor: QuatRx Pharmaceuticals Company; Industry
Eligibility: 40 Years and older · Male only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 16
States / cities: Huntsville, Alabama • Modesto, California • Aurora, Colorado + 13 more

Conditions: Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, PSA Progression, Stage IV Prostate Adenocarcinoma AJCC v7
Interventions: Apalutamide, Stereotactic Body Radiation Therapy; Drug · Radiation
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older · Male only
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Hypogonadism, Primary Hypogonadism, Secondary Hypogonadism
Interventions: Testosterone Undecanoate 750 mg, Testosterone Undecanoate 1000 mg; Drug
Lead sponsor: Endo USA Inc., a Keenova Therapeutics Company; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 531 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Lexington, Massachusetts

Conditions: Secondary Hypogonadism
Interventions: Androxal 12.5 mg or 25 mg, AndroGel 1.62%, Placebo Capsules, Placebo Gel; Drug
Lead sponsor: Repros Therapeutics Inc.; Industry
Eligibility: 18 Years to 60 Years · Male only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 8
States / cities: Jacksonville, Florida • Albany, New York • Raleigh, North Carolina + 5 more

Conditions: Obesity, Prostate Cancer
Interventions: Bariatric Surgery; Other
Lead sponsor: Maimonides Medical Center; Other
Eligibility: 20 Years to 60 Years · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Hypertension
Interventions: leuprolide acetate, Anastrozole; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 40 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy Males, Male Contraceptive
Interventions: First Intervention (7 days), First Washout (7 days), Second Intervention (7 days), Third Intervention (7 days), Second wash-out period; Drug · Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Hypogonadism, Testosterone Deficiency
Interventions: ABT-SLV176; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 80 Years · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 42
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 37 more

Conditions: Sexual Dysfunction, Physiological
Interventions: Testosterone Cream, Estring; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: San Francisco, California

Search by objective public record fields.

T-IR- Study to Understand the Effects of Testosterone and Estrogen on the Body's Response to the Hormone Insulin

Testosterone Pellets Plus Vitamin D and E Versus Vitamin D and E Alone for the Treatment of Peyronie's Disease

TESTO: Testosterone Effects on Short-Term Outcomes in Infants With XXY

Multi-ingredient Supplement for Strength and Power

Treatment of Boys With Precocious Puberty

Pharmacokinetic Study to Determine Time to Steady-state

Bipolar Androgen-based Therapy for Prostate Cancer (BAT)

Theca Cell Function in Adolescents With Polycystic Ovary Syndrome (PCOS)

A Study of Effect of Deodorant and Axillary Hair on Testosterone Absorption in Healthy Participants

Testosterone for Fatigue in Men With MS

The Effects of Testosterone on Prostate Tissue (ACYP-1)

Effects of Testosterone Gel on Carbohydrate and Lipid Metabolism In Elderly Obese Men

Prevention of Recurrent UTI Using Vaginal Testosterone Versus Placebo Placebo

Testosterone Therapy After Hip Fracture in Elderly Women

Optimizing Protein Intake in Older Americans With Mobility Limitations

A Preliminary Clinical Study to Evaluate Fispemifene in the Treatment of Hypogonadism

Apalutamide With or Without Stereotactic Body Radiation in Treating Castration-Resistant Prostate Cancer

Long-term Safety Study of Intramuscular Injections of 750 mg and 1000 mg Testosterone Undecanoate in Hypogonadal Men

A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%

Effect of Lap-Band Induced Weight Loss on Serum PSA Levels

Study of the Effect of Testosterone and Estradiol on NP Responses to Acute and Chronic Salt Loading

Oral T7 Oral Testosterone in Man

An Efficacy and Safety Study of ABT-SLV176 for the Treatment of Hypogonadal Men

Vaginal Testosterone Cream vs ESTRING for Vaginal Dryness or Decreased Libido in Early Stage Breast Cancer Patients